BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26360125)

  • 21. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety Evaluation After Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplant Recipients: A Phase 4, Open-Label, Single-Center Study.
    Kang WH; Song GW; Moon DB; Hwang S; Kim KH; Jung DH; Park GC; Yoon YI; Cho HD; Kim M; Kim SH; Na BG; Kim SM; Yang G; Lee SG
    Transplant Proc; 2021 Dec; 53(10):3000-3006. PubMed ID: 34776265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study.
    Lee EC; Kim SH; Park SJ
    Ann Transplant; 2018 Oct; 23():713-720. PubMed ID: 30310047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily prolonged-release tacrolimus in de novo liver transplantation: a single center cohort study.
    Marubashi S; Wada H; Kobayashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Hepatogastroenterology; 2012 Jun; 59(116):1184-8. PubMed ID: 22172333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
    Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
    Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients.
    Charco R; Caralt M; Lladó L; Valdivieso A; Fabregat J; Matarranz A; Gonzalez-Pinto I; Pardo F; Fábrega E; Bilbao I
    Transplant Proc; 2011 Apr; 43(3):718-23. PubMed ID: 21486582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study.
    Dumortier J; Duvoux C; Dubel L; Bazin F; Houssel-Debry P
    Ann Transplant; 2019 Aug; 24():506-516. PubMed ID: 31451681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single).
    Yang SS; Choi JY; Cho WT; Park JB; Kim SJ
    Transplant Proc; 2015 Apr; 47(3):617-21. PubMed ID: 25891697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
    Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
    Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
    Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
    Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen.
    Meçule A; Tinti F; Bachetoni A; Poli L; D'Alessandro M; Alessandri C; Umbro I; Nofroni I; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1017-9. PubMed ID: 21620040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience.
    Slatinska J; Rohal T; Wohlfahrtova M; Viklicky O
    Transplant Proc; 2013 May; 45(4):1491-6. PubMed ID: 23726604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up.
    Giannelli V; Rossi M; Giusto M; Lucidi C; Lattanzi B; Ruffa A; Ginanni Corradini S; Mennini G; Melandro F; Lai Q; Berloco P; Merli M
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2718-20. PubMed ID: 24174352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.